Castle Biosciences Total Current Liabilities

Castle Biosciences (CSTL) currently reports a total current liabilities of $49M as of March 2026. That compares with $37M in the prior-year period — up 30.8% year over year. Use the charts on this page to explore Castle Biosciences's total current liabilities history and peer comparisons.

Castle Biosciences's total current liabilities increased from $37M to $49M — a 30.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Castle Biosciences reported $49M in total current liabilities as of March 2026. That compares with $37M in the prior-year period — up 30.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $49M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Castle Biosciences, and consider following CSTL for alerts when major investors trade the stock.

Castle Biosciences is classified in the Healthcare sector. On total current liabilities, it currently shows $49M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CSTL with unrelated industries.